REVIEW
Tobramycin (Tobi; Novartis) is the bactericidal aminoglycoside antibiotic most commonly used today for coverage against severe gram-negative respiratory infections (eg, P aeruginosa infection) in patients with CF. 13 Its mechanism is to interfere with bacterial proteins by binding to the 30S ribosomal RNA subunit during protein translation. Recent evidence suggests that aminoglycoside antibiotics can suppress premature termination codons by disrupting translational fidelity and allowing translation to continue to the normal termination of the transcript. 13 Aminoglycosides have additional dose-dependent pleiotropic effects whereby they induce "read-through" of premature stop codons, suppressing a premature stop codon and restoring synthesis to a full-length and functional CFTR protein. 14, 15 Aminoglycoside binding to the ribosome enables read-through inducing misinterpretation of a stop codon, so that ultimately the stop codon directive is "ignored." 16, 17 Gentamicin was the first aminoglycoside investigated for this function. 14,15 Ex vivo administration of gentamicin was shown to increase CFTR function. This application significantly reduced the basal potential difference of nasal epithelium in both homozygous and heterozygous patients (n=19) with a stop codon defect (P=.005). 7, 12 Homozygous carriers of a nonsense mutation had a greater response to gentamicin, with (Table 4) ; the most common adverse effects were headache and cough, with 4 of 89 patients (5%) in 1 study reporting severe pulmonary adverse effects that warranted discontinuation of the drug.
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Class III Defects
Normal CFTR function requires the recognition of adenosine triphosphate or cyclic adenosine monophosphate at the CFTR channel. Class III defects occur when this detection is absent. 5 The most common mutation that underlies this defect is a missense mutation of the amino acid glycine for aspartate at the 551 position (G551D) on the CFTR protein. 5 (Table 3) . 1, 20 One phase III trial found that combining ataluren with tobramycin may reduce its efficacy, suggesting that this combination should not be used. 22 Another antibiotic would therefore need to replace tobramycin should a gram-negative infection develop in a patient receiving ataluren. In these situations, ideal antibiotic therapy would be based on culture and sensitivity results.
Class II Defects
Class II defects of CFTR are present in 90% of all patients with CF ( Table 1) corresponding with an increase in FEV 1 of 367 mL.
These findings corresponded to a 10-fold increase in CFTR-mediated chloride transport in patients with CF and G551D mutations. 29 At the end of the study, patients years or older ( Table 5) . [27] [28] [29] In a randomized, double-blind, placebo-controlled trial 26 of ivacaftor, 84 patients aged 12 years or older with at least 1 G551D CFTR mutation and an FEV 1 of 40% to 90% were treated with ivacaftor for 48 weeks.
After 24 weeks, the predicted FEV 1 values of patients in the ivacaftor group showed absolute increases from a Recommendations: 10 mg/kg at breakfast, 10 mg/kg at lunch, and 20 mg/kg at dinner. Duration of therapy is still under investigation15 at time of publication (Phase III trials). Patients should be monitored for reversible increases in serum creatinine if ataluren is used concomitantly with other nephrotoxic medications. b One patient did not need treatment, and the other was treated with ciprofloxacin. c The CF (cystic fibrosis)-related pulmonary exacerbations were not believed to be caused by ataluren administration.
One patient experienced an onset of symptoms before receiving ataluren and was treated with amikacin. Another patient was removed from the study owing to a chronic infection of Mycobacterium abscessus.
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The results of the TRAFFIC and TRANSPORT trails that studied Lumacaftor in combination with Ivacaftor in patients 12 years of age or older who are homozygous for ΔF508-CFTR mutation showed percent predicted FEV 1 improvement ranging from 2.6% to 4.0% (P≤.001) from baseline compared to placebo with improvements sustained over 24 weeks. 32 There was a mean relative improvement for the Lumacaftor/Ivacaftor treatment group of 4.3% to 6.7% (P≤.001) compared with placebo (P<.001). In vitro research has shown that when lumacaftor and ivacaftor are used in combination, the chloride transport increases to 30%. 26 The most common adverse events reported were infective pulmonary exacerbations, cough, headache, and increased sputum, but the combination therapy was generally well tolerated (Table 6) . 33 Phase III trials are currently planned to evaluate dosing regimens for peak efficacy. 
27,31
The ivacaftor group in that study had a lower proportion of serious adverse events (24% vs 48% in patients receiving placebo); the most common adverse effects were headache, oropharyngeal pain, and upper respiratory tract infections (Table 5) . 27, 28 Ivacaftor is metabolized via the cytochrome P450 3A system into 2 evaluating the effects of lumacaftor and C18 therapy on the ΔF508 mutation has found that this combination can both enhance activation of ΔF508-CFTR and correct the associated folding defect. A phase II study evaluating VX-661 both alone and in combination with ivacaftor is still underway. 35 Other pending studies aim to increase effectiveness with drugs such as N6022 or drug combinations (lumacaftor with ivacaftor or VX-661), without increasing adverse effects.
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Class IV, V, and VI Defects
Mutations to the CFTR gene that involve low function, low production, or membrane instability (class IV, V, and VI defects, respectively) are seen in less than 10%
of patients with CF. In the past 15 years, evidence has suggested that membrane conductance defects caused by ions other than chloride may also potentiate CFTR dysfunction by leading to membrane instability (class VI defects).
11,37 Practicing physicians today can use a small but growing number of drugs to treat patients with CF, but some proposed drugs are not readily available. We recommend that any individuals with a diagnosis of CF be considered candidates for genetic testing to determine which CFTR mutation underlies their disease. This information can then be used to categorize the mutation into a particular drug class (in classes I through VI) and determine the best therapeutic option to maximize functional improvement.
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